Frenck R W, Shannon K M
Department of Pediatrics, US Naval Hospital, Oakland, CA 94627-5000.
Curr Opin Pediatr. 1993 Feb;5(1):94-102. doi: 10.1097/00008480-199302000-00015.
The human recombinant hematopoietic growth factors have attracted widespread interest because of their potential efficacy in a number of clinical settings. Recombinant human erythropoietin is now an established therapy to treat and prevent the anemia associated with chronic renal failure in children and adults. This agent also shows extraordinary promise to stimulate erythrocyte production and reduce transfusion requirements in premature infants. Granulocyte and granulocyte-macrophage colony-stimulating factors stimulate the production and function of myeloid cells and have provided major clinical benefit to children with congenital disorders of neutrophil production. The myeloid growth factors also show great promise in reducing the duration and severity of neutropenias associated with cytotoxic cancer treatment and in improving granulocyte production in patients with human immunodeficiency virus infections.
人类重组造血生长因子因其在多种临床情况下的潜在疗效而引起了广泛关注。重组人促红细胞生成素现已成为治疗和预防儿童及成人慢性肾衰竭相关贫血的既定疗法。这种药物在刺激早产儿红细胞生成和减少输血需求方面也显示出非凡的前景。粒细胞和粒细胞巨噬细胞集落刺激因子可刺激髓细胞的生成和功能，并已为患有先天性中性粒细胞生成障碍的儿童带来了重大临床益处。髓系生长因子在缩短与细胞毒性癌症治疗相关的中性粒细胞减少症的持续时间和减轻其严重程度，以及改善人类免疫缺陷病毒感染患者的粒细胞生成方面也显示出巨大前景。
